DFTX
32.32 USD
-4.16%
Today
-3.82%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 10:59 PM
Tue
4:30 PM ~ 10:59 PM
Wed
4:30 PM ~ 10:59 PM
Thu
4:30 PM ~ 10:59 PM
Fri
4:30 PM ~ 10:59 PM
Sat
Closed
Information
Name
Definium Therapeautics Inc
Currency
USD
Market Cap
4.49B
Avg Daily Volume
2.18M
52 Week High
49.7 USD
52 Week Low
10.465 USD
Trading Hours
See hours
Business Summary
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Top News
Compass
+8.50%
Definium.Therapeautics
-0.34%
COMPASS Pathways rebounds on earnings after selloff driven by rival’s NDA submission
tradingview.com
1d ago
Definium.Therapeautics
-0.34%
Definium Therapeutics to Participate at Upcoming Investor Conferences
tradingview.com
1d ago
Definium.Therapeautics
-0.34%
Weekly Recap: Nov. 9 results webcast and 93,320-share options granted
tradingview.com
2d ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
